CMS Considers Inherent Reasonableness Rule To Lower Pay For Diabetes Test Supplies

The use of a relatively obscure CMS fee-adjustment authority rather than competitive bidding to lower Medicare payment for diabetes testing supplies in the retail setting could be precedent setting.

The diabetes testing supplies industry last week was questioning the “inherent reasonableness” rule that CMS may employ as an alternative to competitive bidding in lowering Medicare payment for diabetic testing supplies sold at retail.

If the agency moves forward with a proposal to use the relatively obscure rule to adjust reimbursement for non-mail order diabetic testing supplies – blood glucose strips, lancets or related...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.